Keywords: low, five-year, resistance, baraclude, drug, major, bristol-myers

Low five-year resistance for Baraclude

Article | 07 April 2008

Print This

US drug major Bristol-Myers Squibb says that new data on its drug Baraclude (entecavir) demonstrate a continued low incidence of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in